Inogen (INGN) Aktie Kurs
Inogen Kurs
Under de senaste 14 åren växte Inogen intäkterna med 19,0 % årligen och nådde 348,67 M USD. Vinst per aktie har vuxit med 58,1 % per år under de senaste 7 åren. För Inogen är nettovinstmarginal på −6,5 % ned jämfört med −1,8 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Inogen är 13,26 USD, cirka över kursen med 144,6 %. Av 8 analytiker ger 7 köpråd — den samlade bedömningen är Köp.
Inogen aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Inogen affärsmodell och aktieanalys
Vanliga frågor om Inogen-aktien
The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.
Inogen Inc is primarily active in the medical device industry.
The main competitors of Inogen Inc in the market are Philips Respironics and Invacare Corporation.
Inogen Inc is a renowned medical technology company specializing in the development and manufacture of portable oxygen concentrators. Founded in 2001 and based in Goleta, California, Inogen has revolutionized the industry by providing innovative and efficient oxygen therapy solutions to patients worldwide. With a strong commitment to enhancing the quality of life for those with respiratory conditions, Inogen has built a solid reputation for its cutting-edge products and exceptional customer service. The company's dedication to research, design, and manufacturing excellence has positioned it as a global leader in the oxygen therapy market, ensuring a brighter and healthier future for individuals in need of respiratory support.
Inogen Inc has achieved several significant milestones over the years. One notable achievement is the development of portable oxygen concentrators, revolutionizing the way individuals with respiratory conditions receive oxygen therapy. In 2008, the company received FDA approval for the Inogen One, its first breakthrough product. Inogen Inc has also expanded its operations globally, catering to a wider customer base across different countries. Furthermore, the company has consistently been recognized for its innovation and contributions to the medical industry. These milestones collectively highlight Inogen Inc's commitment to providing high-quality, life-enhancing solutions for individuals with respiratory needs.
Inogen Inc is primarily present in numerous countries and regions worldwide. With its focus on providing innovative and portable oxygen concentrators, Inogen has established a strong presence in various markets. The company's products and services are available across North America, including the United States and Canada, where it has a significant customer base. In addition, Inogen Inc has expanded its operations to international markets, including Europe, Australia, and Asia. Through its global distribution network and partnerships, Inogen continues to reach and serve customers in diverse geographical locations.
Inogen Inc represents values of innovation, quality, and compassion in providing portable oxygen concentrators and respiratory products. With a corporate philosophy focused on improving the quality of life for individuals with respiratory conditions, Inogen strives to enhance mobility, independence, and freedom for patients worldwide. The company's commitment to developing reliable and efficient solutions is evident through its dedication to research and development, customer service, and manufacturing excellence. Inogen Inc exemplifies its core values by providing market-leading products and exceptional support for patients to maintain an active and fulfilling lifestyle.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 13,26 USD för Inogen-aktien (median: 13,26 USD), vilket innebär +144,6 % mot senaste kurs. Konsensus baseras på 8 analytikerbetyg.
8 analytiker betygsätter för närvarande Inogen-aktien: 7 rekommenderar köp, 1 behåll och 0 sälj. För 2026 väntar sig analytiker att Inogen genererar intäkter på 311,30 M USD och vinst per aktie på −0,96 USD.
Omräknat till aktuell växelkurs handlas Inogen-aktien till 4,94 EUR (5,42 USD).
Inogen-aktien (INGN) är noterad på 4 börser, bland annat: NASDAQ (INGN), SIX (Zürich) (6IO.SW), Frankfurt (6IO.F), Düsseldorf (6IO.DU).
Inogen Inc. is a leading health company specializing in the development, manufacturing, and distribution of respiratory therapy devices. The company's main business is the production of portable oxygen concentrators which can improve the quality of life for patients with health issues. The products offered by Inogen are innovative, space-saving, and lightweight oxygen therapy devices that allow patients to maintain their breathing during daily life activities and have more freedom and independence. These devices are usually smaller and lighter than traditional oxygen systems and designed for easy transportation and operation by patients. Inogen has three main product lines: the Inogen One G5 portable oxygen concentrator, the Inogen at Home electric oxygen concentrator, and the Inogen One G4 portable oxygen concentrator. The Inogen One G5 is a portable oxygen concentrator that offers long battery life and convenient mobility. The Inogen at Home electric oxygen concentrator is a stationary system that provides continuous oxygen supply in the private home environment. The Inogen One G4 is a portable oxygen concentrator that is even smaller and lighter than the Inogen One G5. Inogen also offers accessories for the devices including additional batteries, carrying backpacks, nasal cannulas, and other replacement parts. The company sells its products in the USA and over 30 other countries worldwide. Another business segment of Inogen is the sale of devices to third-party providers including hospitals, doctors, and other healthcare professionals. Inogen provides a comprehensive range of services including service guides, installation, and customer support. Inogen has achieved success due to its technological innovation, high product quality, and customer focus. The company engages in intensive marketing to increase brand awareness and product visibility. Inogen has successful and trained team members in sales, consultation, customer care, and technical support who meet the needs of customers. Inogen follows a co-marketing model that allows them to collaborate with other healthcare partners. These partnerships help the company present its products to a wider customer segment and develop potential business opportunities. As a socially responsible company, Inogen collaborates with various non-profit organizations to achieve its goal of improving the quality of life for patients with respiratory issues. Inogen also strives to act in an environmentally conscious manner and ensures that its devices are environmentally friendly. For example, the devices' batteries are rechargeable and the materials and components are easily reusable. Overall, Inogen's business model focuses on technological innovation, customer orientation, and social responsibility. The company utilizes its core competencies and dedicated employees to create top-notch products and provide high-quality customer service. Inogen is a sound company with robust growth potential and is well-positioned to maintain its market leadership in respiratory therapy.
Omsättningen för förväntad Inogen är 311,30 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Inogen är −26,07 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Inogen är för närvarande −5,65. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Inogen-aktien.
Kurs-försäljningskvoten (P/S) för Inogen är för närvarande 0,47. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Inogen-aktien.
Eulerpool Quality Score för Inogen är 1/10.
ISIN för Inogen är US45780L1044. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Inogen är A1XB32. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Inogen är INGN. Tickersymbolen används för att handla Inogen-aktier på börsen.
Inogen aktie
Inogen Jämförbar grupp
Inogen Ticker
Inogen FIGI
Alla nyckeltal och djupgående analys av Inogen
Vår aktieanalys av Inogen-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Inogen. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: